Gabapentin Tablet, Film Coated
Product Images NDC 68382-205

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 68382-205). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Zydus Pharmaceuticals Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

49957454 Bd5a 4d3c 85cf 6fe78aa2c11e 01

Mathematical formula showing the calculation of creatinine clearance (CLCr) based on age, weight, serum creatinine levels, with a factor adjustment for female patients. The equation is presented in a clear formula format.*

FDA Label Image

49957454 Bd5a 4d3c 85cf 6fe78aa2c11e 02

Chemical structure diagram of the active ingredient gabapentin, showing its molecular framework with a cyclohexane ring and functional groups including an amino group and a carboxylic acid group.*

FDA Label Image

49957454 Bd5a 4d3c 85cf 6fe78aa2c11e 03

Line chart showing mean pain scores over 8 weeks comparing placebo and gabapentin 3600 mg/day. The x-axis represents weeks including a 4-week dose titration period and a 4-week fixed dose period. The y-axis represents mean pain scores ranging from 0 to 10. Gabapentin data points decrease noticeably over time while placebo remains relatively stable.*

FDA Label Image

49957454 Bd5a 4d3c 85cf 6fe78aa2c11e 04

A line graph depicting mean pain scores over seven weeks, comparing placebo and two gabapentin dosages (1800 mg/day and 2400 mg/day). The x-axis shows weeks from baseline to 7, and the y-axis shows the mean pain score from 0 to 10. The graph includes a 3-week dose titration period followed by a 4-week fixed dose period.*

FDA Label Image

49957454 Bd5a 4d3c 85cf 6fe78aa2c11e 05

A bar chart comparing percentage values between placebo (PBO) and Gabapentin (GBP) at doses 1800 mg, 2400 mg, and 3600 mg in two separate studies. Study 1 shows 12% for PBO and 29% for GBP 3600, while Study 2 shows 14% for PBO and 32% and 34% for GBP 1800 and GBP 2400 respectively. Statistical significance is indicated with p-values less than 0.01 and 0.001.*

FDA Label Image

49957454 Bd5a 4d3c 85cf 6fe78aa2c11e 06

A scatter plot displaying differences in percentage on the vertical axis versus daily dose in milligrams on the horizontal axis. The graph compares three studies labeled a, b, and c, represented by different colored squares (black for study a, gray for study b, and white for study c) across daily doses ranging from 600 mg to 1800 mg.*

FDA Label Image

49957454 Bd5a 4d3c 85cf 6fe78aa2c11e 07

Gabapentin Tablets, USP 600 mg film-coated tablets packaging label from Zydus Pharmaceuticals USA Inc. The label displays two oblong tablets imprinted with 'ZE' and '72'. The package contains 100 tablets and is designated Rx only. Storage instructions and dispensing information are included, along with manufacturer and distributor details.*

FDA Label Image

49957454 Bd5a 4d3c 85cf 6fe78aa2c11e 08

Gabapentin Tablets, USP 800 mg film-coated oral tablets by Zydus Pharmaceuticals USA Inc. The label shows an image of a single 800 mg tablet, scored and embossed with 'ZE 71'. The package contains 100 tablets and is Rx only. Additional label information includes storage instructions, dispensing and safety notes, and manufacturer details for Cadila Healthcare Ltd., India.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.